The Neuroendocrine Tumor Research Foundation is excited to share an important update in the field of neuroendocrine tumor (NET) treatment. On August 6, 2024, Exelixis announced that the U.S. Food and Drug Administration (FDA) has accepted their supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX®). This application aims to expand treatment options for adults with advanced, well- or moderately-differentiated pancreatic neuroendocrine tumors (pNET) and extra-pancreatic NETs (epNET).
This application is based on strong results from the Phase 3 CABINET trial, where cabozantinib significantly improved progression-free survival compared to a placebo. With this compelling data, the FDA has set a target action date of April 3, 2025. This date is the deadline by which the FDA aims to complete its review and decide whether to approve the drug for its intended use.
This development represents a meaningful step forward in providing new and effective treatment options for patients with these challenging cancers. We look forward to continued progress and remain dedicated to supporting research that leads to better outcomes for those affected by NETs. Stay connected with us for more updates as we continue our commitment to improving the lives of NET patients.